Alexandria Real Estate Equities, Inc

Alexandria Real Estate Equities, Inc(ARE)の株式分析

$41.620

-0.708 (-1.70%)終値時点

Loading chart…
高値
42.725
始値
42.590
出来高加重平均価格
41.79
出来高
2.20M
時価総額
20.35B
安値
41.020
売買代金
91.94M
EV/EBITDA(TTM)
11.49

Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry.

www.are.com

AI分析 of Alexandria Real Estate Equities, Inc (ARE)

売り

Given the current price of $41.62 and a low RSI of 19.49 indicating oversold conditions, the asset may seem attractive. However, the significant 1-year change of -45.76% and the downgrade from analysts, including BMO Capital reducing its target to $41, suggest ongoing challenges. The high insider selling activity and the need for significant asset sales to de-leverage raise concerns. Therefore, while there might be a potential for a rebound, the risks outweigh the potential rewards at this moment, making it a sell.

アナリスト評価(12)

上値余地 +36.59%
買い
7 買い
5 中立
0 売り
現在: 41.62
安値
41.00
平均
56.85
高値
67.00

BMO Capital

2026-10-12

目標株価

$41

Market Perform

JPMorgan

2026-09-24

目標株価

$56

アンダーウェイト

Evercore ISI

2026-09-21

目標株価

$59

アウトパフォーム

Baird

2026-08-24

目標株価

$52

中立

BofA

2026-08-24

目標株価

$55

中立

バリュエーション指標

Alexandria Real Estate Equities, Inc(ARE)の現在の予想PERは16.69で、5年平均は47.12です。

予想PER

適正
5年平均 P/E
47.12
現在のP/E
16.69
割高
82.81
割安
11.43

予想EV/EBITDA

割安
5年平均 EV/EBITDA
20.35
現在のEV/EBITDA
11.49
割高
28.36
割安
12.34

予想PSR

割安
5年平均 P/S
6.72
現在のP/S
2.89
割高
9.57
割安
3.87

Alphio AI による ARE の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%ARE

$70.33

シナリオ価格

基

基本

基本 · 50%ARE

$69.46

シナリオ価格

弱

弱気

弱気 · 25%ARE

$59.44

シナリオ価格

ARE を保有するクジラ

S

Stichting Pensioenfonds ABP

+ を保有ARE

+2.20%

3か月リターン

C

Clal Financial Management Ltd

+ を保有ARE

-2.97%

3か月リターン

Q

Quinn Opportunity Partners LLC

+ を保有ARE

-6.09%

3か月リターン

C

CenterSquare Investment Management LLC

+ を保有ARE

-8.94%

3か月リターン

ARE のよくある質問 — Alphio AI が回答

Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry. It operates in the Real Estate sector (REAL ESTATE INVESTMENT TRUSTS industry).

Given the current price of $41.62 and a low RSI of 19.49 indicating oversold conditions, the asset may seem attractive. However, the significant 1-year change of -45.76% and the downgrade from analysts, including BMO Capital reducing its target to $41, suggest ongoing challenges. The high insider selling activity and the need for significant asset sales to de-leverage raise concerns. Therefore, while there might be a potential for a rebound, the risks outweigh the potential rewards at this moment, making it a sell.

12 analysts cover ARE: 7 rate it Buy, 5 Hold and 0 Sell. The average price target is 56.85.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める